Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG119

—

36b2c29f-ddd4-5125-8525-9ea4a4458bf4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TGF_BETA_SIGNALING+0.530
  • ANGIOGENESIS+0.500
  • TNFA_SIGNALING_VIA_NFKB+0.493
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.492
  • ESTROGEN_RESPONSE_EARLY+0.443
  • ESTROGEN_RESPONSE_LATE+0.400
  • COAGULATION+0.393
  • HEDGEHOG_SIGNALING+0.392
  • UV_RESPONSE_DN+0.341
  • CHOLESTEROL_HOMEOSTASIS+0.330

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.499
  • MYC_TARGETS_V1-0.367
  • MYC_TARGETS_V2-0.351
  • DNA_REPAIR-0.346
  • E2F_TARGETS-0.328
  • INTERFERON_ALPHA_RESPONSE-0.282
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.197
  • INTERFERON_GAMMA_RESPONSE-0.155
  • ALLOGRAFT_REJECTION-0.114
  • UNFOLDED_PROTEIN_RESPONSE-0.108

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG115
mng-umap@100
——0.975
2TCGA-22-4605-01A-21R-2125-07
lung-landscapes@6
—cohortSQ10.883
320030015.LumB
breast-umap@18
—A0.883
4SRR15069612
head-neck@1
——0.867
56b548699-9440-4acc-86b6-faeb367454a2
colon-landscapes@1
——0.858
6TCGA-CV-5970-01A-11R-1686-07
head-neck@1
——0.855
7TCGA-E2-A153-01A-12R-A12D-07
breast-umap@18
—A0.855
84c7083b3-eccc-4d80-a31d-6fd3cd0222b4
colon-landscapes@1
——0.855
9TCGA-A2-A0EO-01A-11R-A034-07
breast-umap@18
—A0.851
10e074ff82-1def-4bfc-8293-6b69f8984046
colon-landscapes@1
——0.846

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 34 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TGF_BETA_SIGNALING0.530Inavolisib— uncovered
ANGIOGENESIS0.500Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.493Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.492Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.443Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.400Idelalisib— uncovered
COAGULATION0.393Binimetinib— uncovered
HEDGEHOG_SIGNALING0.392Inavolisib— uncovered
UV_RESPONSE_DN0.341Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.330Remibrutinib— uncovered
HYPOXIA0.326Idelalisib— uncovered
ANDROGEN_RESPONSE0.299Inavolisib— uncovered
APICAL_JUNCTION0.298Inavolisib— uncovered
APOPTOSIS0.289Idelalisib— uncovered
MYOGENESIS0.287Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.267Inavolisib— uncovered
APICAL_SURFACE0.258Temsirolimus— uncovered
UV_RESPONSE_UP0.225Idelalisib— uncovered
COMPLEMENT0.221Inavolisib— uncovered
PANCREAS_BETA_CELLS0.216Cobimetinib— uncovered